A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

Area of Science:

• Oncology
• Cell Biology
• Cancer Research

Background:

• Cancer cell heterogeneity influences treatment response.
• A small subpopulation of drug-tolerant cells exists in human tumor cell lines.
• Understanding drug tolerance is crucial for effective cancer therapy.

Purpose of the Study:

• To investigate the mechanisms of reversible drug tolerance in cancer cells.
• To identify therapeutic targets for eliminating drug-tolerant cancer cell subpopulations.
• To explore the role of phenotypic heterogeneity in cancer survival.

Main Methods:

• Modeling acute responses to anticancer agents in human tumor cell lines.
• Analyzing the role of IGF-1 receptor signaling in drug tolerance.
• Investigating the involvement of histone demethylase RBP2/KDM5A in the drug-tolerant phenotype.
• Assessing the effects of IGF-1 receptor inhibitors and chromatin-modifying agents.

Main Results:

• A small subpopulation of reversibly drug-tolerant cells was consistently detected.
• These cells exhibit >100-fold reduced drug sensitivity.
• Drug tolerance is maintained via IGF-1 receptor signaling and an RBP2-dependent altered chromatin state.
• The drug-tolerant phenotype is dynamically regulated and transiently acquired.

Conclusions:

• Cancer cell populations utilize a dynamic survival strategy involving transient drug tolerance.
• Individual cells can reversibly adopt a drug-tolerant state to protect the population.
• Targeting IGF-1 receptor signaling or chromatin modification can selectively eliminate drug-tolerant cells.
• This presents a potential therapeutic opportunity to overcome treatment resistance.